Abstract
Background: Debate continues whether primary surgery or neo-adjuvant chemotherapy (NACT) or primary debulking surgery (PDS) should be offered in advanced epithelial ovarian cancer as frontline therapy. Since 2015, there has been a paradigm shift at Tata Medical center, whereas increasing number of patients are being offered PDS and a quality improvement programme was initiated. Recently, ESGO in October 2015 has published a document indicating 10 quality indicators for cytoreductive surgery in advanced ovarian cancer surgery. Aim: We compared our performance against all 10 quality indicators. Results: Primary cytoreduction rate has increased from 20% in 2012 to >70% at the end of 2015. Optimal cytoreduction rates were obtained in 90% cases and recently complete (CCO/CC1) cytoreduction rates are being achieved in >80% cases. All 10 quality indicators were achieved successfully including prospective documentation of morbidity and surgical findings in all cases. Morbidity figures are showing a downwards trend after the initial learning curve. Conclusions: Implementation of a quality improvement programme is the key to overcome the barriers of implementing a cytoreductive program in advanced ovarian cancer. However, standards similar to developed countries can be achieved through a dedicated team effort.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
